Evidence map›Paper›PMID 40874188›Full record

ArticleOpen forum infectious diseases2025

Immune Response to MVA-BN and Prior Smallpox Vaccination in People With HIV or at Risk for HIV Acquisition.

Yijia Li, Michael B Townsend, Shanshan Li, Quinn E Testa, Tom Medvec, Elizabeth A Thompson, Frank J Palella, Matthew J Mimiaga, James B Brock, Maria L Alcaide and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Yijia LiSchool of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.ORCID https://orcid.org/0000-0001-5300-0571
Michael B TownsendPoxvirus and Rabies Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-0354-7437
Shanshan LiPoxvirus and Rabies Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Quinn E TestaSchool of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.ORCID https://orcid.org/0009-0005-8509-8733
Tom MedvecSchool of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Elizabeth A ThompsonDepartment of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
Frank J PalellaFeinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Matthew J MimiagaFielding School of Public Health and David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
James B BrockDivision of Infectious Diseases, Department of Internal Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Maria L AlcaideMiller School of Medicine, University of Miami, Miami, Florida, USA.ORCID https://orcid.org/0000-0003-4648-0145
Anandi N ShethDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-6305-2727
Michelle Floris-MooreDivision of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0009-0007-9515-2857
Aruna ChandranDepartment of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0002-7411-2852
Audrey L FrenchDepartment of Internal Medicine, University of Illinois Chicago, Chicago, Illinois, USA.
Phyllis C TienDepartment of Medicine, University of California San Francisco, San Francisco, California, USA.
Daniel J MerensteinSchool of Medicine, Georgetown University, Washington, DC, USA.ORCID https://orcid.org/0000-0002-8808-6907
Michael AugenbraunDepartment of Medicine, SUNY Downstate Health Science University, Brooklyn, New York, USA.
Anjali SharmaDepartment of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.ORCID https://orcid.org/0000-0003-3717-025X
Caitlin A MoranDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0001-8436-0465
Charles R RinaldoSchool of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Bernard J C MacatangaySchool of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Panayampalli S SatheshkumarPoxvirus and Rabies Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Ken S HoSchool of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.ORCID https://orcid.org/0000-0001-7973-1268

Funding

University of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Savita Pahwa · 2007 to 2026
$33.8M
NIAID NIH HHS P30 AI073961
6 · The paper itself

Abstract

Little is known about the serologic response elicited by the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccination (JYNNEOS) against mpox in elderly individuals with or without HIV. In this study, we measured levels of antibody against orthopoxvirus in selected participants (n = 114) with HIV or at risk for HIV acquisition from the Multicenter AIDS Cohort Study/Women's Interagency HIV Study Combined Cohort Study, who had no prior reported history of mpox. Participants reported MVA-BN vaccination history via questionnaires. The median age was 64 years, 24.6% were female, and 46% were HIV seropositive. Twenty out of 114 participants received at least 1 dose of MVA-BN. We found that MVA-BN induced sustained IgG levels regardless of HIV status, even up to 1 year. Birth before 1973 was correlated with higher IgG. MVA-BN-unvaccinated individuals with HIV had lower IgG than those without HIV. Although limited by small sample size, our study is among the first to assess anti-orthopoxvirus antibodies specifically in a vulnerable, older population and stratified by HIV status.

Indexed as

antibody levelHIVmpoxMVA-BN

Identifiers

PMID40874188
PMCPMC12378729

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.